Balding and Hair Loss References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001 Jul;11(4):309-14.
  2. Stene JJ. [Alopecia areata and treatment]. Rev Med Brux. 2004 Sep;25(4):A282-A285.
  3. Price VH. Androgenetic alopecia in adolescents. Cutis. 2003 Feb;71(2):115-21.
  4. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle. J Dermatol Sci. 2004 Jun;35(1):9-18.
  5. Hibino T, Nishiyama T. Role of TGF-beta2 in the human hair cycle. J Dermatol Sci. 2004 Jun;35(1):9-18.
  6. Whiting DA. Chronic telogen effluvium. Dermatol Clin. 1996 Oct;14(4):723-31.
  7. Hadshiew IM, Foitzik K et al. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol. 2004 Sep;123(3):455-7.
  8. Murray JC. Pregnancy and the skin. Dermatol Clin. 1990 Apr;8(2):327-34.
  9. Gollnick H, Blume U et al. [Adverse drug reactions on hair]. Z Hautkr. 1990 Dec;65(12):1128-34.
  10. Pierard-Franchimont C, Pierard GE. [How I explore...Hair loss in cancer patients]. Rev Med Liege. 2004 Sep;59(9):525-9.
  11. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
  12. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
  13. Yamada K, Goto S. Bilateral subthalamic nucleus stimulation results in reversal of alopecia in Parkinson's disease. Parkinsonism Relat Disord. 2004 Aug;10(6):353-5.
  14. Borum ML, Cannava M. Diffuse alopecia associated with omeprazole. Am J Gastroenterol. 1997 Sep;92(9):1576.
  15. Sarris E, Tsele E et al. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis. 2003 May;41(5):E15.
  16. Ettefagh L, Nedorost S et al. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004 Aug;140(8):1012.
  17. Gottenberg JE, Venancie PY et al. Alopecia areata in a patient with rheumatoid arthritis treated with leflunomide. J Rheumatol. 2002 Aug;29(8):1806-7.
  18. Chave TA, Mortimer NJ et al. Agranulocytosis and total scalp alopecia following acitretin. Br J Dermatol. 2003 May;148(5):1063-4.
  19. Kohno Y, Ishii A et al. [A case of hair loss induced by carbamazepine]. Rinsho Shinkeigaku. 2004 Jun;44(6):379-81.
  20. Gautam M. Alopecia due to psychotropic medications. Ann Pharmacother. 1999 May;33(5):631-7.
  21. Shelley ED, Shelley WB. Alopecia and drug eruption of the scalp associated with a new beta-blocker, nadolol. Cutis. 1985 Feb;35(2):148-9.
  22. Hashimoto K. The structure of human hair. Clin Dermatol. 1988 Oct;6(4):7-21.
  23. Paus R, Foitzik K. In search of the "hair cycle clock": a guided tour. Differentiation. 2004 Dec;72(9-10):489-511.
  24. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002 Dec 30;198(1-2):89-95.
  25. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
  26. Alexis AF, Dudda-Subramanya R et al. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol. 2004 Nov;14(6):364-70.
  27. Drake L, Hordinsky M et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999 Oct;41(4):550-4.
  28. FMPHLSG., The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.
  29. Pitts WR, Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004 Jul;140(7):885-6.
  30. Bramson HN, Hermann D et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997 Sep;282(3):1496-502.
  31. Ellis CN, Brown MF et al. Sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002 Apr;46(4):541-4.
  32. Burke KE. Hair loss. What causes it and what can be done about it. Postgrad Med. 1989 May 1;85(6):52-73, 77.
  33. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002 Jul;27(5):396-404.
  34. Shimizu Y, Sakai M et al. Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible-type nitric oxide synthase in keratinocytes. J Dermatol. 1997 Feb;24(2):80-7.
  35. Prager N, Bickett K et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. J Altern Complement Med. 2002 Apr;8(2):143-52.
  36. Liao S, Hiipakka RA. Selective inhibition of steroid 5 alpha-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun. 1995 Sep 25;214(3):833-8.
  37. Cos P, De Bruyne T et al. Proanthocyanidins in health care: current and new trends. Curr Med Chem. 2004 May;11(10):1345-59.
  38. Yuen Kah Hay, B. Randomized clinical trial of tocotrienols supplementation vs. placebo for androgenetic alopecia. School of Pharmaceutical Sciences, Universiti Sains, Malaysia. Submitted for publication 2009.
  39. Neve HJ, Bhatti WA et al. Reversal of Hair Loss following Vertical Gastroplasty when Treated with Zinc Sulphate. Obes Surg. 1996 Feb;6(1):63-5.
  40. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993 Jul;101(1 Suppl):143S-7S.